vincristine

P1, N=24, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> May 2026

P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027

P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027

P2, N=33, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P1, N=16, Not yet recruiting, National Cancer Institute (NCI)

P3, N=310, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

The patient was referred to a sarcoma center where he was started on systemic chemotherapy with a VAC/IE (vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide) regimen. CONCLUSIONS This case highlights the diagnostic complexity of DSRCT, particularly in atypical liver-dominant presentations, and reinforces the importance of comprehensive tissue sampling and molecular confirmation to guide early, appropriate therapy. Continued research into targeted strategies is crucial to improve outcomes in this aggressive malignancy.

Subsequent treatment with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) resulted in a marked clinical and radiological response. This case highlights an atypical, pain-dominant presentation of acute SVC obstruction mimicking acute aortic dissection. It emphasizes the importance of considering venous etiologies early to avoid diagnostic delay in patients presenting with acute chest pain and limb vascular abnormalities.

By establishing specific correlations between biochemical and behavioral parameters, this study provides mechanistic insights into VCR-induced neurotoxicity. It proposes 4-PSQ as a promising therapeutic candidate for preventing or reversing chemotherapy-related cognitive and emotional dysfunctions.

The combination therapy based on the in situ vaccine FOLactis and intravenous PD-1 monoclonal antibody showed a certain degree of anti-tumor effect, and was safe and well tolerated in patients with advanced hepatic malignancies.

The patient received six cycles of rituximab-based chemotherapy (R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), followed by cranial radiotherapy, and achieved complete remission after 12 months. While MZL subtypes typically behave indolently, DLBCL variants require aggressive multimodal therapy. This report highlights the importance of histopathologic confirmation in all dural-based lesions and demonstrates that early multidisciplinary management, including surgery, rituximab-based chemotherapy, and radiotherapy, can result in sustained remission even in highly aggressive forms.

The median number of therapeutic lines was four: 82% received chemotherapy (weekly vinblastine in 55%, vincristine/carboplatin regimen in 45%), 64% received MAPK pathway-targeted therapy, and 18% underwent radiotherapy...Conventional low-grade glioma chemotherapy constitutes the current treatment backbone, while MAPK pathway-targeted therapies show promising potential. Further studies and the establishment of an international registry are crucial to better characterize aggressive subtypes and optimize management strategies.